MA-STILLA-TECHNOLOGIES
23.11.2021 15:08:20 CET | Business Wire | Press release
Stilla Technologies , the multiplex digital PCR company, today announced it has raised €31.3 million in the form of €11.3 million of convertible bonds and €20 million in loan financing. In addition to new funding from existing investors Illumina Ventures, Kurma Partners, TusPark Capital Management, LBO France, BNP Paribas Developpement and Eurazeo, Stilla has attracted investment from leading life science firm Casdin Capital and from the European Investment Bank (EIB).
Stilla will use the funds to further expand its global commercial presence and develop its next generation digital PCR platform. Most recently, the innovation leader launched the six-color naica® system, the industry’s highest multiplexing digital PCR system, already in high demand and being used by researchers and clinicians across a breadth of applications.
“In the context of the Covid-19 pandemic which highlighted the need for accurate and reliable diagnostic tools, the EIB is pleased to provide this investment to a dynamic and fast-growing company at the forefront of digital PCR innovation,” said Ambroise Fayolle, Vice President of the EIB. “Thanks to the European guarantee put in place by the EU Member States and deployed by the EIB, Europe is investing more in health, which is both a factor of competitiveness and attractiveness for the continent and brings a better quality of life to its inhabitants.”
“We are excited to continue supporting Stilla Technologies alongside other premier investors,” said Nick Naclerio, Founding Partner at Illumina Ventures. “We see incredible promise in Stilla’s platform to accelerate the utilization of genomics data in routine translational research and clinical settings.”
“This latest financing will enable us to continue to support our commercial growth in the North American and European markets and our strategic distribution networks in Asia, as well as sustain our pace of product innovation as we look to our next phase,” said Philippe Mourere, President and CEO, Stilla Technologies.
About Stilla Technologies
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking Crystal Digital PCR™ solution, the naica® system , is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China. To learn more, visit www.stillatechnologies.com and connect with Stilla on Twitter , LinkedIn and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005853/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Launches Cash Tender Offer11.3.2026 13:25:00 CET | Press release
THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE MARKET ABUSE REGULATION (EU) 596/2014. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT)) OR IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (SEE “OFFER AND DISTRIBUTION RESTRICTIONS” BELOW). SES (the “Offeror”) announces today that it is inviting holders of its outstanding €625,000,000 Deeply Subordinated Fixed Rate Re
Thredd and Cross River to Accelerate Expansion into the US Market for Global Fintechs11.3.2026 13:01:00 CET | Press release
B4B Payments scales U.S. operations through collaboration Thredd, the AI-first issuer processing platform, today announced a strategic alliance with Cross River Bank (“Cross River”), a technology infrastructure provider that offers embedded financial solutions. The relationship is designed to accelerate the entry of international fintechs into the United States. This collaboration leverages Thredd’s global expertise and technology stack with Cross River’s proprietary core infrastructure, established market leadership and regulatory expertise, creating a seamless pathway for innovative payment solutions to launch and scale in the U.S. As part of this agreement, Thredd becomes one of Cross River’s select strategic processing partners outside of the bank’s own stack. The arrangement enables Thredd to introduce a curated pipeline of high-potential fintech clients from various geographic regions*.1 In turn, Thredd’s clients benefit from Cross River’s proven ability to deliver compliant, sca
SLB Provides Update on Middle East Operations and First Quarter Outlook11.3.2026 13:00:00 CET | Press release
SLB (NYSE: SLB) continues to closely monitor the unfolding situation in the Middle East and adapt its operations. The safety and security of SLB’s employees is the highest priority, and the company has activated local and regional crisis response teams that are meeting daily. Travel to and transit through the region have been suspended, and the company has begun to demobilize operations in a few countries in response to customer actions to safeguard personnel and facilities. These measures will continue as long as necessary until the environment in the region has stabilized. SLB is working closely with local authorities and its customers to monitor the situation and will begin a phased resumption of full activity as conditions allow. SLB revenue for the first quarter will be lower than expected, and the company expects to incur additional costs resulting in an impact of approximately 6-9 cents of earnings per diluted share for the first quarter. Given the dynamic nature of the environm
IQM Delivers Fourth Quantum Computer in Finland, Operational at Aalto University11.3.2026 11:32:00 CET | Press release
This is the fourth quantum computer deployed by IQM to customers in Finland to boost research and education in a growing ecosystem. The system named Aalto Q20 quantum computer is online at Aalto University and will enable students and scientists a unique first-hand access to a world-class quantum computer. The university will use the quantum computer to perform scientific experiments on advanced level and to support national and European quantum research activities. IQM Quantum Computers, the global leader in deployed on-premises, full-stack superconducting quantum computers, today announced the launch of Aalto Q20 quantum computer in Finland, reinforcing its commercial leadership in the quantum industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311215316/en/ Ribbon cutting of the Aalto Q20 quantum computer delivered by IQM. The 20-qubit system, which is operational at Aalto University, is the fourth quantum compute
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 11:00:00 CET | Press release
Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissionsBespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resiliencePartnership aligns with the science-based climate commitments of both companies Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom